LONDON, June 21 (Reuters) - Shire Plc said on Thursday the U.S. Food and Drug Administration (FDA) intended to approve Intuniv, its extended-release, non-stimulant treatment for attention deficit ...

A federal judge on Tuesday certified a class of drug distributors and other companies who say they paid inflated prices for Shire PLC's ADHD drug Intuniv due to an improper patent lawsuit settlement ...

Alembic is launching Guanfacine Extended-Release tablets in dosage strengths of 1 mg, 2 mg, 3 mg and 4 mg. The product is the generic of Takeda’s Intuniv Extended-Release tablets. Guanfacine ...

Medically reviewed by Patricia Mikula, PharmD Key Takeaways ADHD is often treated with medications and behavioral therapy. Stimulants are first-choice medications for children with ADHD. ADHD symptoms ...